Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 91-100 of 146 for Ovarian

Edit search filters
  1. Study To Evaluate The Diagnostic Performance Of GEH300079 (68Ga) Injection PET/CT For Detection Of PC In Patients With Colorectal, Gastric, Ovarian, Or Pancreatic Cancers (PERISCOPE)

    Rochester, MN

  2. A Open Label Study Of The Efficacy And Safety Of PD0332991 A Selective Inhibitor Of The Cyclin Dependent Kinases 4 And 6 In Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency And Low P16 Expression

    Rochester, MN

  3. A Study To Evaluate Bleomycin, Carboplatin, Etoposide, Or Cisplatin In Treating Pediatric And Adult Patients With Germ Cell Tumors

    Rochester, MN

  4. Outcomes After Secondary Cytoreductive Surgery With Or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed By Systemic Combination Chemotherapy For Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer

    Rochester, MN

  5. Evaluating The Addition Of Adjuvant Chemotherapy To Ovarian Function Suppression Plus Endocrine Therapy In Premenopausal Patients With PN0-1, ER-Positive/HER2-Negative Breast Cancer And An Oncotype Recurrence Score Less Than Or Equal To 25

    Scottsdale/Phoenix, AZ, Jacksonville, FL, La Crosse, WI, Mankato, MN, Rochester, MN

  6. A Study Of Mirvetuximab Soravtansine Vs. Investigator's Choice Of Chemotherapy In Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, Or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. Understanding The Challenges, Behavioral Patterns, And Preferences Towards Participation In Clinical Trials In Minority Patient Populations

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. Olaparib And Onalespib In Treating Patients With Solid Tumors That Are Metastatic Or Cannot Be Removed By Surgery Or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, Or Triple-Negative Breast Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. A Study To Evaluate Exercise For Cancer Patients At Risk Of Falling

    Rochester, MN

  10. Metabolite Levels In Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors

    Rochester, MN

.

Mayo Clinic Footer